Generic Orbactiv Availability
Last updated on May 7, 2025.
Orbactiv is a brand name of oritavancin, approved by the FDA in the following formulation(s):
ORBACTIV (oritavancin diphosphate - powder;intravenous)
-
Manufacturer: MELINTA THERAP
Approval date: August 6, 2014
Strength(s): EQ 400MG BASE/VIAL [RLD]
Is there a generic version of Orbactiv available?
No. There is currently no therapeutically equivalent version of Orbactiv available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Orbactiv. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Methods of treatment using single doses of oritavancin
Patent 8,420,592
Issued: April 16, 2013
Inventor(s): Lehoux Dario & Parr Thomas R. & Moeck Gregory & Etienne Pierre
Assignee(s): The Medicines CompanyGlycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.
Patent expiration dates:
- August 29, 2029✓
- August 29, 2029
-
High purity oritavancin and method of producing same
Patent 9,649,352
Issued: May 16, 2017
Inventor(s): Rafai Far; Adel et al.
Assignee(s): THE MEDICINES COMPANY (Parsippany, NJ); ABBVIE INC. (Chicago, IL)Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.
Patent expiration dates:
- July 16, 2035✓
- July 16, 2035
-
Methods of treating bacterial infections using oritavancin
Patent 9,682,061
Issued: June 20, 2017
Inventor(s): Lehoux Dario & Parr & Jr. Thomas & Moeck Gregory
Assignee(s): THE MEDICINES COMPANYThe present invention is directed to methods of treating a bacterial infection in a subject through the administration of a therapeutically effective amount of a glycopeptide antibiotic to a subject having a bacterial infection. The effective amount of the glycopeptide antibiotic that is administered to the subject provides a fraction of the glycopeptide antibiotic administered to the subject bound to serum proteins within the subject and within a selected range.
Patent expiration dates:
- April 26, 2030✓
- April 26, 2030
More about Orbactiv (oritavancin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: glycopeptide antibiotics
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.